Poster: A Genome-Scale PARPi Screen for Synthetic Lethality
At Myllia, we’ve performed a genome-scale CRISPR KO screen in HeLa cells to identify novel or well-known genes that are involved in DNA damage repair and would resemble gene pairs with PARP.
PARP inhibition is a therapeutic strategy used in cancer treatment aiming to prevent cancer cells from efficiently repairing their DNA, thus leading to genomic instability and cell death, particularly in tumors with BRCA1/2 mutations. At Myllia, we’ve performed a genome-scale CRISPR KO screen in HeLa cells to identify novel or well-known genes that are involved in DNA damage repair and would resemble gene pairs with PARP.
Our results indicate that most identified genes are associated with different DDR mechanisms, including BER, ICL repair, homologous recombination (HR), and NHEJ or Alt-NHEJ pathways. Comparing our hit list with data derived from 23 publicly available screens, we can confirm a total of 109 hits across 14 different cell lines, hence demonstrating how synthetic lethality CRISPR screens can support target identification for novel combination therapies.
Submit your credentials and explore our capabilities and functional read-outs!